Pyxis Oncology, Inc.
PYXS
$1.14
-$0.05-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -- | -- |
| Cost of Revenue | -100.00% | -- | -- | -- | -- |
| Gross Profit | -100.00% | -- | -- | -- | -- |
| SG&A Expenses | -30.29% | -27.05% | -28.94% | -12.82% | -16.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.36% | 1.61% | -20.44% | -21.57% | -28.81% |
| Operating Income | -29.32% | 18.47% | 36.39% | 36.97% | 43.09% |
| Income Before Tax | -68.50% | -7.73% | 39.17% | 40.15% | 46.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.75% | -4.80% | 39.17% | 40.15% | 46.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.75% | -4.80% | 39.17% | 40.15% | 46.76% |
| EBIT | -29.32% | 18.47% | 36.39% | 36.97% | 43.09% |
| EBITDA | -31.38% | 20.26% | 38.61% | 39.11% | 45.26% |
| EPS Basic | -12.73% | 31.46% | 58.91% | 55.80% | 56.94% |
| Normalized Basic EPS | 9.42% | 47.91% | 58.90% | 55.80% | 56.95% |
| EPS Diluted | -12.73% | 31.46% | 58.91% | 55.80% | 56.94% |
| Normalized Diluted EPS | 9.42% | 47.91% | 58.90% | 55.80% | 56.95% |
| Average Basic Shares Outstanding | 38.76% | 46.50% | 44.78% | 40.04% | 29.83% |
| Average Diluted Shares Outstanding | 38.76% | 46.50% | 44.78% | 40.04% | 29.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |